HSDTNasdaqFinance ServicesUS GAAP · USD

Solana Co

Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset. The company also retains a neurotechnology business focused on non-implantable technologies for neurological wellness, including products and related development, licensing, or acquisition activities.

Revenue6.0m USD
+1,057.1 %y/y
Operating profit (EBIT)-244m USD
−1,653.9 %y/y
EBIT margin-4,052.5%
−1,378.9 ppy/y
Net income-40.9m USD
−248.2 %y/y
Free cash flow-16.5m USD
−49.5 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-250-200-150-100-50050m USD2020: 0.66 m USD2020: EBIT -14 m USD20202021: 0.52 m USD2021: EBIT -18 m USD20212022: 0.79 m USD2022: EBIT -16 m USD20222023: 0.64 m USD2023: EBIT -12 m USD20232024: 0.52 m USD2024: EBIT -14 m USD20242025: 6.0 m USD2025: EBIT -244 m USD20256.0-244
RevenueOperating profit (EBIT)

Business

Share of revenue
Digital asset treasury60 %

Acquisition and holding of SOL as the company's primary treasury reserve asset.

Onchain yield activities10 %

Staking, lending, and other ecosystem activities intended to generate income from SOL holdings.

Neurotechnology products25 %

Non-implantable neurological wellness technologies, including the PoNS-related business.

Licensing and technology development5 %

Development, licensing, or acquisition of technologies tied to neurological wellness and blockchain-enabled platforms.

Products

Reported · share of revenue
76.6%23.4%FY2025100 %
  • Products76.6 %
  • Other23.4 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

The company serves two distinct constituencies: public market investors seeking exposure to Solana through a listed treasury vehicle, and end users or channel buyers of its neurotechnology offerings. In the treasury model, the economic 'customer' is effectively the capital markets investor base, while the operating business still sells neurotechnology products and related services to healthcare-oriented users and distributors.

Public market investors

Buy the listed equity for exposure to SOL per share and treasury asset appreciation.

Neurotechnology end users

Buy or use non-implantable neurological wellness products such as PoNS-related offerings.

Healthcare channel partners

Support commercialization, distribution, or licensing of neurotechnology products.

Crypto ecosystem counterparties

Provide exchanges, custodial, staking, or lending infrastructure for SOL activities.

Strategy

The company’s stated strategy is to maximize SOL per share by building and scaling a Solana treasury through capital markets activity and onchain opportunities. It also seeks optionality from staking, lending, and ecosystem participation while maintaining a separate neurotechnology platform that can be developed, licensed, or acquired over time.

Scale SOL holdingsShort term

A larger SOL treasury is intended to increase exposure to Solana's ecosystem and support the company's treasury thesis.

Use capital markets efficientlyShort term

ATM sales, PIPEs, and other financing tools are used to fund SOL accumulation and treasury expansion.

Monetize SOL through onchain activityMedium term

Staking and lending can create income streams from treasury assets if counterparties and market conditions allow.

Preserve neurotechnology optionalityLong term

The legacy operating business provides a second platform for product development, licensing, or acquisition.

Geography

Q2/2025

The company is headquartered in the United States and reports product sales in the United States and Canada. Its Solana treasury strategy is tied to global crypto markets, but custody, exchange access, and regulatory oversight are especially important in the U.S. because the company relies on U.S.-based exchanges, custodians, and securities markets.

Canada79 %
United States21 %

Share of the revenue the company reports by geography.

Risks

The company is exposed to the volatility, custody, and regulatory risks of holding a concentrated SOL treasury, where price declines or ecosystem disruptions can directly affect its asset base and market value. It also faces execution risk in using exchanges, custodians, and capital markets to acquire SOL, while its legacy neurotechnology business carries commercialization and product-development risk.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Concentrated SOL treasury exposure1SOL price volatility2Regulatory uncertainty for crypto assets3Custody and private key loss4Exchange and counterparty dependence5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Concentrated SOL treasury exposureImpact: HighLikelihood: Medium

    The company intends to hold a large share of assets in one volatile token, limiting diversification.

    Exposure: Treasury asset value and equity market valuation

  2. SOL price volatilityImpact: HighLikelihood: Medium

    Large swings in SOL price can materially affect the company's financial condition and stock price.

    Exposure: Treasury holdings and investor sentiment

  3. Regulatory uncertainty for crypto assetsImpact: HighLikelihood: Medium

    New or changing laws could affect SOL ownership, transferability, or market access.

    Exposure: U.S. and foreign crypto regulation

  4. Custody and private key lossImpact: HighLikelihood: Low

    Loss, theft, or destruction of keys could prevent access to custodially held SOL.

    Exposure: Digital asset custody

  5. Exchange and counterparty dependenceImpact: MediumLikelihood: Medium

    The company relies on third-party exchanges and custodians for purchases and storage.

    ExposureTradingCustodySettlement
  6. Neurotechnology commercialization riskImpact: Medium

    The legacy operating business depends on product adoption, reimbursement, and development success.

    Exposure: Product sales and licensing

Accounting

Judgemental items
Derivative liability fair value

Reported gains or losses on derivative instruments can materially affect quarterly earnings.

Impact: Nonoperating income and net loss

Digital asset treasury accounting

SOL holdings and related custody arrangements require careful treatment of valuation and access rights.

Impact: Balance sheet presentation and risk disclosures

Revenue recognition for product sales

Legacy product revenue is small and can be sensitive to shipment timing and unit volumes.

Impact: Quarterly revenue comparability

Equity financing and warrant accounting

ATM sales, PIPEs, and warrant inducements affect dilution and may involve complex equity classification.

Impact: Share count and capital structure

Potential staking/lending income

If the company generates yield from SOL, revenue recognition and counterparty assessment become important.

Impact: Future operating and nonoperating income

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026